Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

124.12 -3.58 (-2.80%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
Via Stocktwits
Why Is Avidity Biosciences Stock Down 20% Pre-market Today?
Via Stocktwits
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud... 
Via Chartmill
Topics Economy
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
Via Stocktwits
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
Via Stocktwits
How Is The Market Feeling About Novartis?
 
Via Benzinga
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Novartis agreed to buy a cardiovascular-focused biotech company 
Via Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company. 
Via Investor's Business Daily
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback 
Via MarketBeat
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction. 
Via Benzinga
Novartis AG (NYSE:NVS) Offers a Compelling Mix of Dividend Yield, Profitability, and Financial Health
Discover Novartis (NVS), a top dividend stock with a strong 3.37% yield, high profitability, and a sustainable payout for reliable income. 
Via Chartmill
P/E Ratio Insights for Novartis
 
Via Benzinga
1 High-Yield Vanguard Dividend Fund to Buy Hand Over Fist
This international dividend powerhouse quietly delivered 26.6% returns this year -- more than doubling the S&P 500 while paying triple the income. 
Via The Motley Fool
Topics ETFs Stocks
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. 
Via The Motley Fool
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms
Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025. 
Via Benzinga
Topics Artificial Intelligence
Palantir Hosts Eighth AIPCon. Stays Above 50-Day Line. Is PLTR Stock A Buy?
Palantir stock bulls tout the software maker's AI strategy and strong U.S. government business amid a lofty valuation for PLTR stock. 
Via Investor's Business Daily
Topics Artificial Intelligence ETFs Government
Why Did Bollinger Innovations Stock Plunge 18% Today?
The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned... 
Via Stocktwits
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug. 
Via Investor's Business Daily
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting. 
Via Benzinga
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing. 
Via Chartmill
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
These companies have successfully navigated similar obstacles before. 
Via The Motley Fool
Topics Intellectual Property
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
2 Dividend Stocks to Buy and Hold
These stocks look like they can weather almost any storm. 
Via The Motley Fool
Topics Artificial Intelligence Cannabis Government
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation. 
Via Chartmill
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.